Summit Therapeutics Share Discussion Threads

[chrisatrdg] 11/10/2017 17:17

Thanks waterloo01 & agree with your comments.

I thought that the C-Diff package was exceptional & Vickers showed great confidence plus good back up from the others.Clearly C-Diff is the ace in the pack & DMD is still a risk for which they need better answers on 'at what stage & time will they know it works'.

In summary I still feel safe with my investment but only because C-Diff will underpin the current low share price so would not envisage a reduction from where I am now.

[waterloo01] 11/10/2017 16:14

Interesting that Wilcox confirmed my doubts about poop treatment and it's wider effect on microbiom.

[waterloo01] 11/10/2017 16:06

Yes, c.diff much more robust but feel that the answers on utrophin tells me they (and the FDA) will need more data as it's not a 'clean' picture. Nothing new in that as they have always said they will do a placebo trial but not sure the next data is going to be knock out.

[chrisatrdg] 11/10/2017 15:35

Hi waterloo01 - I think you are picking up on Summits answer to questions asked about 'when do you know'.I was a little surprised at answers & not sure their answer gave confidence to those asking the question.It made me think 'oh dear' your comment now makes me feel worse.

C-Diff so far feeling more assured.

[waterloo01] 11/10/2017 15:11

Yes,they are shooting in the dark!

[chrisatrdg] 11/10/2017 15:03

Been listening to Summit presentation this afternoon,currently on a break,does anyone have any thoughts on what we have heard so far?

[football] 10/10/2017 10:00

Did I miss something in yesterday's news that was bad or are we just being screwed around with the share price

[waterloo01] 09/10/2017 14:48

Some bigger buys appearing 2 x 25k shares at £2.00 would suggest either director or II buying IMO.

[chrisatrdg] 09/10/2017 12:10

Todays RNS is further proof that Summit are on track with their C-Diff drug hopefully the market will soon appreciate the true potential value of the drug.

SUMMIT HIGHLIGHTS MICROBIOME PRESERVATION DURING RIDINILAZOLE TREATMENT AT ID WEEK 2017

[chrisatrdg] 04/10/2017 21:45

Well found waterloo01.

[chrisatrdg] 04/10/2017 14:56

RNS - Posters from this weeks conference

[waterloo01] 03/10/2017 09:43

Not unexpected but patience required. What will the next news be? RDZ further grant funding/partner? ETZ update? More might be clear after the event next week.

[hugus maximus] 03/10/2017 09:31

Indeed luminoso ... all rather dull since the money raise.

[luminoso] 02/10/2017 22:42

Sarepta seem to have gained a bit at our expense on nasdaq today.

[hugus maximus] 02/10/2017 21:47

AIM & NASDAQ are close to parity tonight. I didn't think we'd ever see the 180's again.

[chrisatrdg] 02/10/2017 12:12

RNS looks good to me a chance to be a window for Summit to display its science & a chance for questions.Looking forward to listening in & maybe further updates.

[waterloo01] 29/9/2017 15:42

This causing a kerfuffle in the USA as people search and find SAE's (often out of context). SRPT has dropped though because of it. Happy hunting!



The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA’s Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this information.

Edit: site is down as so many are searching it and no concerns with Summit thankfully.

[football] 29/9/2017 09:35

Up a few percent in the US last night and down over a few percent here doesn't make sense

[waterloo01] 26/9/2017 14:54

"The summary says it all. Regulators at the FDA reiterated a series of damning conclusions, with no positive data to consider. PTC’s post hoc analyses of failed studies, they concluded, are unconvincing in light of the fact that the results were “clearly negative”, while highlighting the “misleading nature of exploratory analyses of negative trials.” And there’s no reason to believe that any future trials of this drug will prove it can be effective."

I think we've known that for awhile!

[luminoso] 25/9/2017 12:12

Nice share price reaction to rns

[chrisatrdg] 25/9/2017 12:10

RNS Today:

SUMMIT JOINS cTAP IN COLLABORATIVE EFFORT TO ENHANCE THE DEVELOPMENT OF UTROPHIN MODULATORS AND OTHER TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY




cTAP link:

[waterloo01] 22/9/2017 19:13

Good to see Nasdaq getting close to $13 again. Bodes well.

[someuwin] 21/9/2017 16:14

Theres been a lot of Canaccord Genuity holding RNSs popping up on all sorts of stocks recently.

I believe the reason is because Canaccord have recently bought out Hargreave Hale.

So just re-stating existing holdings.